Ganciclovir is widely used as prophylactic and preemptive therapy, as well as treatment, for CMV infection following BMT. We report a case treated with ganciclovir 5 days a week. Following escalation of the ganciclovir dose to a twice daily dose to treat CMV antigenaemia, he developed encephalopathy. His encephalopathy resolved with withdrawal of ganciclovir. Ganciclovir encephalopathy has been described in other groups of patients but has not been reported following BMT to date. With its widespread use this complication is likely to be seen more often. Keywords: BMT; cytomegalovirus (CMV) infection; pre-emptive therapy; ganciclovir therapy; encephalopathy CMV infection remains one of the major obstacles to the success of allogeneic bone marrow transplantation. Because of this, prophylactic or pre-emptive therapy with ganciclovir is used widely.
Summary:
Ganciclovir is widely used as prophylactic and preemptive therapy, as well as treatment, for CMV infection following BMT. We report a case treated with ganciclovir 5 days a week. Following escalation of the ganciclovir dose to a twice daily dose to treat CMV antigenaemia, he developed encephalopathy. His encephalopathy resolved with withdrawal of ganciclovir. Ganciclovir encephalopathy has been described in other groups of patients but has not been reported following BMT to date. With its widespread use this complication is likely to be seen more often. Keywords: BMT; cytomegalovirus (CMV) infection; pre-emptive therapy; ganciclovir therapy; encephalopathy CMV infection remains one of the major obstacles to the success of allogeneic bone marrow transplantation. Because of this, prophylactic or pre-emptive therapy with ganciclovir is used widely.
1,2 The use of ganciclovir in BMT patients is associated with various systemic side-effects which may require temporary cessation of therapy. [3] [4] [5] [6] [7] [8] Ganciclovir induced neurotoxicity is documented in the literature. [3] [4] [5] [6] [7] [8] [9] Most case reports are associated with renal failure 5 and in HIV positive patients. [6] [7] [8] We describe a patient with neurological side-effects in the setting of allogeneic transplantation.
Case report
An 11-year-old boy with ALL in CR3 underwent BMT from a matched unrelated donor. His conditioning regimen consisted of TBI in fractionated doses (165 cGy twice a day) from day −7 to day −4 (total dose 1320 cGy), cyclophosphamide 60 mg/kg on days −3 and −2 (total dose 8800 mg) and ATG 30 mg/kg for 3 days on day −3 to day −1 (total dose 6750 mg +1, 10 mg/m 2 on day +3, +6, and +10. As he was CMV positive, he received unscreened irradiated blood products and intravenous acyclovir 500 mg/m 2 /dose every 8 h during his peritransplant period for CMV prophylaxis. On day +21, following neutrophil recovery, his CMV prophylaxis was changed to ganciclovir 5 mg/kg/day as a single daily dose 5 days a week. He was monitored for CMV activation in the form of CMV antigenaemia (pp65 antigen positive cells in buffy coat smear).
His early post-transplant period was uneventful, with minimal supportive care. He showed evidence of engraftment on day +14 (ANC Ͼ0.5 × 10 9 /l). He developed hypertension and electrolyte disturbances secondary to CsA which were well controlled by nifidipine, oral magnesium and calcium supplementation, respectively.
On day +28, he developed an erythematous maculopapular pruritic rash distributed mainly on the neck and upper limbs. A viral illness or GVHD was considered. Due to persistence of the rash he was commenced on prednisolone 2 mg/kg/day. Blood cultures during this episode were negative for bacteria, viruses and fungi. The rash fluctuated but was never severe.
On day +35 he had CMV activation in the form of high level of CMV antigenaemia (Ͼ50 pp65 antigen positive cells/2 × 10 5 PMNC). He was admitted for pre-emptive therapy with ganciclovir 5 mg/kg/dose twice daily, 2 together with CMV hyperimmune globulin. His other medications were CsA, prednisolone, co-trimoxazole, nifedipine and itraconazole. His LFTs were mildly elevated with an ALT of 145 U/l (normal range 10-50 U/l) and a GGT of 151 U/l (normal range 6-20 U/l), but with a normal bilirubin. His creatinine remained elevated between 77 to 110 mol/l (normal range 30-75 mol/l) and his CsA levels ranged between 102 to 158 ng/ml (normal range 100-350 ng/ml).
After 7 days of twice daily ganciclovir he started complaining of low back pain and inability to walk, and required a morphine infusion to control his pain. Clinical examination was normal apart from tenderness over the lower thoracolumbar spine. Imaging studies (X-ray thoracolumbar spine and bone scan) were normal. Ten days after commencing twice daily ganciclovir he started to become drowsy and lethargic. The drowsiness progressively increased and he remained sleepy but arousable after verbal stimuli. He had intermittent periods of alertness and somnolence. On the 13th day he became confused which pro-gressed to hallucinations. This episode was complicated by hyponatremia with a serum sodium 122 mmol/l (normal level 133-143 mmol/l). His higher functions continued to deteriorate despite correction of the hyponatremia. Throughout this episode he remained hemodynamically stable. In view of rising creatinine levels, CsA and ganciclovir were withheld. Extensive investigation failed to identify an infectious aetiology for his mental state. Blood cultures remained sterile and serological studies were negative for Mycoplasma and HHV-6. A lumbar puncture was performed on the 14th day of admission. His CSF was clear and contained no white cells and a normal protein concentration. It was negative for malignant cells, fungi, bacteria, mycoplasma, protozoa and viruses. PCR failed to detect evidence of HHV-6 or Mycoplasma in the CSF or blood. CSF viral cultures were unsuccessful. An MRI brain scan showed increased signal intensity over brainstem suggestive of toxic or viral encephalopathy. (Figures 1 and 2) . EEG revealed generalised slow wave pattern. Two days after stopping ganciclovir his neurological status started to steadily improve. He became more alert and oriented. Since he continued to have CMV antigenaemia he was commenced on foscarnet. CsA was reintroduced. The back pain resolved and he was discharged 5 days after withdrawal of ganciclovir. The CMV antigenaemia cleared on day +69 while he was on foscarnet, although he needed temporary cessation of foscarnet and CsA due to a worsening renal status. This was not accompanied by any recurrence of his neurological symptoms. Since the clinical improvement was significant, we did not repeat his imaging studies.
Discussion
Highly effective agents against CMV, such as ganciclovir, foscarnet and CMV hyperimmunoglobulin have reduced the impact of CMV infection following BMT. However these drugs can cause considerable adverse effects. Common adverse effects associated with ganciclovir therapy include fever, nausea, vomiting, diarrhoea, vomiting, leukopenia, anaemia, and thrombocytopenia. 3, 10 There has been concern about neurological toxicity of acyclovir requiring discontinuation of therapy. 11 Ganciclovir, an acyclic nucleoside, being structurally similar to acyclovir, does have a potential of causing adverse neurological symptoms. Since it is primarily excreted through the kidneys as the parent compound, renal dysfunction increases the risk of neurotoxicity. [3] [4] [5] [6] [7] [8] 10 Anecdotal reports about ganciclovir-induced seizures, psychosis, behavioural changes, sensory hallucinations have been described in patients with renal failure and AIDS. Seizures and psychiatric disturbances have been reported and confirmed by rechallenging the patient with ganciclovir and documenting the reappearance of neurological adverse effects. [5] [6] [7] [8] These cases typically report a latent period between commencement of ganciclovir and the neurotoxicity. [5] [6] [7] [8] Our patient showed a clear temporal relationship between increasing the doses of ganciclovir and onset of symptoms. His back pain also improved with withdrawal of ganciclovir and the drug information sheet mentions back pain as a possible side-effect. Failure to demonstrate an infectious cause and improvements in neurological status after stopping ganciclovir strongly favour the medication as the cause of his encephalopathy. We did not consider a ganciclovir rechallenge due to the potential of causing clinical deterioration.
It has been postulated that there may be some interaction between ganciclovir and CsA, leading to aggravation of CsA-induced neurotoxicity. 9 However, in our case we found no evidence of CsA neurotoxicity; his spinal fluid biochemistry was normal, MRI did not reveal any white matter degeneration (Figures 1 and 2 ) and we successfully reintroduced CsA without any adverse effects.
Ganciclovir does penetrate the blood-brain barrier and high CSF ganciclovir levels are felt to explain the observed neurotoxicity. 5 It may take some time to achieve toxic levels in CSF, thus explaining the typical latent period between start of ganciclovir and onset of neurological symptoms. This may explain why patients may tolerate a lower dose without problems, but develop symptoms with escalation in dose, particularly in association with renal impairment, which would further increase blood and presumably CSF levels, as in our case.
The appearance of neurological dysfunction in an immunosuppressed patient poses a diagnostic challenge. With the increasing use of ganciclovir in clinical practice more cases with neurotoxicity are likely to be encountered. It will be of interest to see if other cases show the same pattern of increased signal intensity over the brain stem on MRI.
